Vincent T Ma

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Systemic Lupus Erythematosus

Metastatic Colorectal Cancer

Combination Therapy

Tyrosine Kinase

Top Venues

Pigment cell & melanoma research

Clinical cancer research : an official journal of the American Association for Cancer Research

University of Michigan

University of Nevada Reno (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Michigan Jul 01 2018

United States

Hematology/Oncology Fellow :: Internal Medicine

University of Michigan

United States

Internal Medicine Resident :: Internal Medicine

Education History

University of Nevada Reno

United States

BSC

Publications

Vincent Pozorski, Yeonhee Park, Yusuf Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair, Mark R Albertini, Vincent T Ma
Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy. Pigment cell & melanoma research 36 (6) (2023)
Vincent T Ma, Christopher D Lao, Leslie A Fecher, Elena Schiopu
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14 (8) (2022)
Kelly L Harms, Lili Zhao, Bryan Johnson, Xiao-Ming Wang, Shannon Carskadon, Nallasivam Palanisamy, Daniel R Rhodes, Rahul Mannan, Josh N Vo, Jae Eun Choi, May P Chan, Douglas R Fullen, Rajiv M Patel, Javed Siddiqui, Vincent T Ma, Steven Hrycaj, Scott A McLean, Tasha M Hughes, Christopher K Bichakjian, Scott A Tomlins
Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (9) (2021)
Vincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, Sara Journey, Zoey Chopra, Alangoya Tezel, Bruce G Redman, Leslie A Fecher, Michael D Green, Ajjai S Alva, Christopher D Lao
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. Pigment cell & melanoma research 34 (3) (2020)